A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design

Peter Lommer Kristensen, Ulrik Pedersen-Bjergaard, Henning Beck-Nielsen, Kirsten Nørgaard, Hans Perrild, Jens Sandahl Christiansen, Tonny Jensen, Hans-Henrik Parving, Birger Thorsteinsson, Lise Tarnow, Peter Lommer Kristensen, Ulrik Pedersen-Bjergaard, Henning Beck-Nielsen, Kirsten Nørgaard, Hans Perrild, Jens Sandahl Christiansen, Tonny Jensen, Hans-Henrik Parving, Birger Thorsteinsson, Lise Tarnow

Abstract

Background: Severe hypoglycaemia still represents a significant problem in insulin-treated diabetes. Most patients do not experience severe hypoglycaemia often. However, 20% of patients with type 1 diabetes experience recurrent severe hypoglycaemia corresponding to at least two episodes per year. The effect of insulin analogues on glycaemic control has been documented in large trials, while their effect on the frequency of severe hypoglycaemia is less clear, especially in patients with recurrent severe hypoglycaemia. The HypoAna Trial is designed to investigate whether short-acting and long-acting insulin analogues in comparison with human insulin are superior in reducing the occurrence of severe hypoglycaemic episodes in patients with recurrent hypoglycaemia. This paper reports the study design of the HypoAna Trial.

Methods/design: The study is a Danish two-year investigator-initiated, prospective, randomised, open, blinded endpoint (PROBE), multicentre, cross-over trial investigating the effect of insulin analogues versus human insulin on the frequency of severe hypoglycaemia in subjects with type 1 diabetes. Patients are randomised to treatment with basal-bolus therapy with insulin detemir / insulin aspart or human NPH insulin / human regular insulin in random order. The major inclusion criterion is history of two or more episodes of severe hypoglycaemia in the preceding year.

Discussion: In contrast to almost all other studies in this field the HypoAna Trial includes only patients with major problems with hypoglycaemia. The HypoAna Trial will elucidate whether basal-bolus regimen with short-acting and long-acting insulin analogues in comparison with human insulin are superior in reducing occurrence of severe hypoglycaemic episodes in hypoglycaemia prone patients with type 1 diabetes. http://www.clinicaltrials.gov: NCT00346996.

Figures

Figure 1
Figure 1
Graphic presentation of the HypoAna study which is a prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia.

References

    1. Banck-Petersen P, Larsen T, Pedersen-Bjergaard U, Bie-Olsen L, Høi-Hansen T, Thorsteinsson B. Concerns about hypoglycaemia and late complications in patients with insulin-treated diabetes. Eur Diabetes Nurs. 2007;4:113–118. doi: 10.1002/edn.91.
    1. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med. 1991;8:217–222. doi: 10.1111/j.1464-5491.1991.tb01575.x.
    1. Jørgensen HV, Pedersen-Bjergaard U, Rasmussen AK, Borch-Johnsen K. The impact of severe hypoglycemia and impaired awareness of hypoglycemia on relatives of patients with type 1 diabetes. Diabetes Care. 2003;26:1106–1109. doi: 10.2337/diacare.26.4.1106.
    1. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev. 1999;15:42–46. doi: 10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>;2-B.
    1. Auer RN. Hypoglycaemic Brain Damage. Metab Brain Dis. 2004;19:169–175.
    1. Leckie AM, Graham MK, Grant JB, Ritchie PJ, Frier BM. Frequency, severity, and morbidity of hypoglycemia occurring in the workplace in people with insulin-treated diabetes. Diabetes Care. 2005;28:1333–1338. doi: 10.2337/diacare.28.6.1333.
    1. ter Braak EW, Appelman AM, van de LM, Stolk RP, van Haeften TW, Erkelens DW. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care. 2000;23:1467–1471. doi: 10.2337/diacare.23.10.1467.
    1. UK Hypoglycaemia Study Group . Risk of hypoglycaemia in types 1 and 2 diabetes effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–1147.
    1. Macleod KM, Hepburn DA, Frier BM. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med. 1993;10:238–245. doi: 10.1111/j.1464-5491.1993.tb00051.x.
    1. Gold AE, Macleod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17:697–703. doi: 10.2337/diacare.17.7.697.
    1. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus. Lancet. 2001;357:1248–1253. doi: 10.1016/S0140-6736(00)04405-6.
    1. Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV, Matthews DR, Hougaard P, Thorsteinsson B. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479–486. doi: 10.1002/dmrr.482.
    1. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Prediction of severe hypoglycaemia by Angiotensin-converting enzyme activity and genotype in type 1 diabetes. Diabetologia. 2003;46:89–96.
    1. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP. DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med. 2005;22:749–755. doi: 10.1111/j.1464-5491.2005.01501.x.
    1. Kristensen PL, Hansen LS, Jespersen MJ, Pedersen-Bjergaard U, Beck-Nielsen H, Christiansen JS, Nørgaard K, Perrild H, Parving H-H, Thorsteinsson B, Tarnow L. Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Res Clin Pract. 2011;96:17–23.
    1. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;19:CD003287.
    1. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab. 2009;11:372–378. doi: 10.1111/j.1463-1326.2008.00976.x.
    1. Kølendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, Gall MA, Heller SR. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med. 2006;23:729–35. doi: 10.1111/j.1464-5491.2006.01862.x.
    1. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622–9. doi: 10.1007/s00125-004-1365-z.
    1. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P, Landin-Olsson M, Hylleberg B, Lang H, Draeger E. Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care. 2004;27:1081–7. doi: 10.2337/diacare.27.5.1081.
    1. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care. 2003;26:590–6. doi: 10.2337/diacare.26.3.590.
    1. Bulsara MK, Holman CD, Davis EA, Jones TW. Evaluating risk factors associated with severe hypoglycaemia in epidemiology studies-what method should we use? Diabet Med. 2004;21:914–919. doi: 10.1111/j.1464-5491.2004.01250.x.
    1. Ferguson SC, Strachan MW, Janes JM, Frier BM. Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes Metab Res Rev. 2001;17:285–291. doi: 10.1002/dmrr.202.
    1. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, Bellaire S, Raben A. Insulin Aspart Pregnancy Study Group. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care. 2007;30:771–776. doi: 10.2337/dc06-1887.
    1. Thomas RM, Aldibbiat A, Griffin W, Cox MA, Leech NJ, Shaw JA. A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. Diabet Med. 2007;24:778–83. doi: 10.1111/j.1464-5491.2007.02196.x.
    1. American Diabetes Association Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes. Diabetes Care. 2005;28:1245–1249.
    1. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev. 2003;19:232–240. doi: 10.1002/dmrr.377.
    1. Hoi-Hansen T, Pedersen-Bjergaard U, Thorsteinsson B. Classification of hypoglycemia awareness in people with type 1 diabetes in clinical practice. Diabetes Complications. 2010;24:392–397. doi: 10.1016/j.jdiacomp.2009.07.006.
    1. Euroqol website.
    1. EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16:199–208.
    1. Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, Balkrishnan R. Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther. 2004;26:565–578. doi: 10.1016/S0149-2918(04)90059-8.
    1. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek G, Butterfield J. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care. 1987;10:617–621. doi: 10.2337/diacare.10.5.617.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel